The purity of recombinant mIL-13 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-13 and staining overnight with Coomassie Blue.Learn more about how we get our images
The proliferation of B9 cells treated with increasing concentrations of mIL-13 was assessed. After 48 hour treatment with mIL-13, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.Learn more about how we get our images
Western blot analysis of extracts from TF-1 cells untreated or treated with mIL-13 for 10 minutes, using Phospho-Stat6 (Tyr641) (C11A12) Rabbit mAb Antibody #9364 (upper) and Stat6 Antibody #9362 (lower).Learn more about how we get our images
Recombinant mouse IL-13 (mIL-13) Ser26-Phe131 (Accession #NP_032381) was expressed in human 293 cells at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-13. All lots are greater than 98% pure.
Recombinant mIL-13 contains no "tags" and the nonglycosylated protein has a calculated MW of 11,677. DTT-reduced and non-reduced protein migrate as 12-20 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal SVSLP of recombinant mIL-13 was verified by amino acid sequencing.
The bioactivity of recombinant mIL-13 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.5 - 20 ng/ml.
Less than 0.01 ng endotoxin/1μg mIL-13.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-13. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
IL-13 is produced by T cells and is important in the TH2 response. IL-13 targets include B cells, eosinophils, fibroblasts, mast cells and macrophages (1-3). IL-13 binds specifically to IL-13Rα1 that complexes with IL-4Rα to form the Type II IL-4R. Jak1 and Tyk2 are activated and signal through Stat3 and Stat6 (4). IL-13Rα2 is a different gene product, lacks the intracellular domain, does not complex with IL-4Rα and does not signal (1,4,5). The extracellular domain of IL-13Rα2 is often elevated in diseased states. IL-13 plays key roles in airway hyperresponsiveness (AHR) of allergic asthma (1,6,7) and modulates resistance to parasitic organisms (1).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.
|5242SC||5 µg (With Carrier)||$ 215.0|
|5242SF||5 µg (Carrier Free)||$ 215.0|